XHKG2552
Market cap192mUSD
Dec 23, Last price
1.52HKD
1D
-0.65%
1Q
27.73%
IPO
-81.44%
Name
Hua Medicine
Chart & Performance
P/E
—
P/S
18.28
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.25%
Rev. gr., 5y
53.03%
Revenues
77m
+335.31%
Net income
-211m
L+3.66%
CFO
889m
P
Earnings
Mar 26, 2025
Profile
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 76,610 335.31% | 17,599 | ||||||
Cost of revenue | 414,676 | 284,717 | 321,670 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (338,066) | (267,118) | (321,670) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 259 | 5,217 | ||||||
Tax Rate | ||||||||
NOPAT | (338,066) | (267,377) | (326,887) | |||||
Net income | (211,234) 3.66% | (203,766) -38.43% | (330,951) -16.52% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 9,886 | 11,001 | 10,349 | |||||
BB yield | -0.51% | -0.30% | -0.29% | |||||
| Debt | ||||||||
Debt current | 41,471 | 55,413 | 13,296 | |||||
Long-term debt | 170,001 | 105,828 | 129,760 | |||||
Deferred revenue | 1,245,905 | 611,362 | 288,106 | |||||
Other long-term liabilities | 611,362 | 288,106 | ||||||
Net debt | (1,249,352) | (329,391) | (532,182) | |||||
| Cash flow | ||||||||
Cash from operating activities | 889,367 | (230,114) | (272,981) | |||||
CAPEX | (9,741) | (27,467) | (66,891) | |||||
Cash from investing activities | 8,077 | (4,752) | (68,219) | |||||
Cash from financing activities | 69,068 | 21,476 | (6,134) | |||||
FCF | (12,786) | (550,595) | (359,969) | |||||
| Balance | ||||||||
Cash | 1,460,824 | 490,632 | 675,238 | |||||
Long term investments | ||||||||
Excess cash | 1,456,994 | 489,752 | 675,238 | |||||
Stockholders' equity | (5,829,163) | (5,641,476) | (5,459,300) | |||||
Invested Capital | 7,343,973 | 7,241,362 | 6,557,371 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 977,055 | 966,730 | 957,489 | |||||
Price | 1.97 -47.33% | 3.74 -1.32% | 3.79 -34.43% | |||||
Market cap | 1,924,798 -46.76% | 3,615,571 -0.37% | 3,628,882 -33.95% | |||||
EV | 675,446 | 3,286,180 | 3,096,700 | |||||
EBITDA | (301,828) | (235,341) | (290,081) | |||||
EV/EBITDA | ||||||||
Interest | 7,907 | 3,667 | 3,950 | |||||
Interest/NOPBT | ||||||||